8-K
Cytek Biosciences Reports Third Quarter 2026 Financial Results and Narrows Full-Year Revenue Outlook
8-K
Cytek Biosciences, Inc. Adopts Amended and Restated Bylaws
8-K
Jury Finds in Cytek’s Favor on Three of Four Asserted Claims in Patent Infringement Case
8-K
Cytek Biosciences Reports Second Quarter 2026 Financial Results and Updates Full Year Guidance
8-K
Cytek Biosciences, Inc. Announces Severance and Consulting Agreements with Former Chief Legal Officer
8-K
Cytek Biosciences, Inc. Announces Departure of Chief Legal Officer
